Search

Your search keyword '"Nador G"' showing total 3 results
Start Over Author "Nador G" Publisher nature publishing group
3 results on '"Nador G"'

1. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens

Author

Nosari, A, Cairoli, R, Ciapanna, D, Gargantini, L, Intropido, L, Baraté, C, Scarpati, B, Santoleri, L, Nador, G, Pezzetti, L, Morra, E, Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté C, Scarpati B, Santoleri L, Nador G, Pezzetti L, Morra E., Nosari, A, Cairoli, R, Ciapanna, D, Gargantini, L, Intropido, L, Baraté, C, Scarpati, B, Santoleri, L, Nador, G, Pezzetti, L, Morra, E, Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté C, Scarpati B, Santoleri L, Nador G, Pezzetti L, and Morra E.

Abstract

Systematic data on the ability of pegfilgrastim to mobilize stem cells after chemotherapy are scarce. We evaluated the efficacy of a single 6mg dose of pegfilgrastim for mobilizing peripheral blood stem cells (PBSC) in aggressive lymphoma patients. Between July 2004 and October 2005, 17 aggressive non-Hodgkin's lymphoma and 11 poor-risk Hodgkin's lymphoma were treated with cycles containing cisplatin-aracytin. At the end of chemotherapy, the patients received 6mg of pegfilgrastim. Duration of grade 4 neutropenia, adverse events, time to neutrophil recovery, peak and harvest of CD34+ cells were recorded. Twenty-seven out of 28 patients harvested a median of 17.3 × 106/CD34+ cells (range 2.5-28.9) after a median of 9 days (range 8-12 days), with a single apheresis procedure in 25 cases. All patients had grade 3-4 neutropenia, median duration 3 days. The only adverse event was mild bone pain. To date, 13 patients have been autografted with a median of 15.4 × 106 CD34+ pegfilgrastim-mobilized cells per kg (range 2.5-28.9) with rapid and sustained engraftment. Mobilization, harvesting and autografting of pegfilgrastim-mobilized PBC can be successfully achieved in pretreated patients with aggressive lymphoma.

Published
2006

2. Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.

Author

Olechnowicz SWZ, Weivoda MM, Lwin ST, Leung SK, Gooding S, Nador G, Javaid MK, Ramasamy K, Rao SR, Edwards JR, and Edwards CM

Subjects
Adiponectin antagonists & inhibitors, Animals, Bone Marrow drug effects, Cell Proliferation drug effects, Disease Models, Animal, Gene Expression Regulation, Neoplastic drug effects, Humans, Imidazoles pharmacology, Mice, Multiple Myeloma complications, Multiple Myeloma genetics, Multiple Myeloma pathology, NF-kappa B antagonists & inhibitors, Neuroglia metabolism, Neuroglia pathology, Osteoblasts drug effects, Pain complications, Pain genetics, Pain pathology, Peptides pharmacology, Piperidines pharmacology, Quinoxalines pharmacology, Stromal Cells drug effects, Tumor Microenvironment drug effects, Adiponectin genetics, Multiple Myeloma drug therapy, Nerve Growth Factor genetics, Pain drug therapy, Tumor Necrosis Factor-alpha genetics
Abstract

Interactions between multiple myeloma (MM) and bone marrow (BM) are well documented to support tumour growth, yet the cellular mechanisms underlying pain in MM are poorly understood. We have used in vivo murine models of MM to show significant induction of nerve growth factor (NGF) by the tumour-bearing bone microenvironment, alongside other known pain-related characteristics such as spinal glial cell activation and reduced locomotion. NGF was not expressed by MM cells, yet bone stromal cells such as osteoblasts expressed and upregulated NGF when cultured with MM cells, or MM-related factors such as TNF-α. Adiponectin is a known MM-suppressive BM-derived factor, and we show that TNF-α-mediated NGF induction is suppressed by adiponectin-directed therapeutics such as AdipoRON and L-4F, as well as NF-κB signalling inhibitor BMS-345541. Our study reveals a further mechanism by which cellular interactions within the tumour-bone microenvironment contribute to disease, by promoting pain-related properties, and suggests a novel direction for analgesic development.

Published
2019
Full Text
View/download PDF

3. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens.

Author

Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté C, Scarpati B, Santoleri L, Nador G, Pezzetti L, and Morra E

Subjects
Adult, Aged, Antimetabolites, Antineoplastic administration & dosage, Antimetabolites, Antineoplastic adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin administration & dosage, Cisplatin adverse effects, Cytarabine administration & dosage, Cytarabine adverse effects, Female, Filgrastim, Hodgkin Disease complications, Humans, Lymphoma, Non-Hodgkin complications, Male, Middle Aged, Neutropenia etiology, Pain, Polyethylene Glycols, Recombinant Proteins, Transplantation, Autologous, Antigens, CD34, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Granulocyte Colony-Stimulating Factor administration & dosage, Hematopoietic Stem Cell Mobilization adverse effects, Hodgkin Disease therapy, Lymphoma, Non-Hodgkin therapy, Peripheral Blood Stem Cell Transplantation adverse effects
Abstract

Systematic data on the ability of pegfilgrastim to mobilize stem cells after chemotherapy are scarce. We evaluated the efficacy of a single 6 mg dose of pegfilgrastim for mobilizing peripheral blood stem cells (PBSC) in aggressive lymphoma patients. Between July 2004 and October 2005, 17 aggressive non-Hodgkin's lymphoma and 11 poor-risk Hodgkin's lymphoma were treated with cycles containing cisplatin-aracytin. At the end of chemotherapy, the patients received 6 mg of pegfilgrastim. Duration of grade 4 neutropenia, adverse events, time to neutrophil recovery, peak and harvest of CD34+ cells were recorded. Twenty-seven out of 28 patients harvested a median of 17.3 x 10(6)/CD34+ cells (range 2.5-28.9) after a median of 9 days (range 8-12 days), with a single apheresis procedure in 25 cases. All patients had grade 3-4 neutropenia, median duration 3 days. The only adverse event was mild bone pain. To date, 13 patients have been autografted with a median of 15.4 x 10(6) CD34+ pegfilgrastim-mobilized cells per kg (range 2.5-28.9) with rapid and sustained engraftment. Mobilization, harvesting and autografting of pegfilgrastim-mobilized PBC can be successfully achieved in pretreated patients with aggressive lymphoma., (Published online 31 July 2006.)

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results